RNA241220C35000
- 12.32
- 0.000.00%
Avidity Biosciences Newsroom
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RNA Stock Hits Record High on Entering the Cardiac Disease Space
Avidity Biosciences: Expanding Horizons in Precision Cardiology With New Genetic Targets
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Jumps 16%; Reaches All-time High
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $65
Avidity Biosciences (RNA) Gets a Buy From Barclays
Avidity Biosciences Analyst Ratings
Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology
Buy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology Advancements
Chevron, Super Micro Computer Top List of Most Shorted Large-cap Stocks in October, Hazeltree Says
Avidity Biosciences Unveils Advances in Cardiology Research
Express News | Avidity-Aoc 1086,Aoc 1072 Well Tolerated Without Any Effect on Electrocardiogram Parameters for Evaluating Cardiac Safety in Preclinical Studies